Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CHMP Issues Positive Opinion for Samsung Bioepis and Biogen's Biosimilar Aflibercept, OPUVIZ™
Latest Hotspot
3 min read
CHMP Issues Positive Opinion for Samsung Bioepis and Biogen's Biosimilar Aflibercept, OPUVIZ™
25 September 2024
OPUVIZ has received a recommendation for approval for adult patients in the treatment of neovascular (wet) age-related macular degeneration (AMD).
Read →
Tolebrutinib Delays Disability Progression by 31% in Phase 3 MS Study
Latest Hotspot
3 min read
Tolebrutinib Delays Disability Progression by 31% in Phase 3 MS Study
25 September 2024
Tolebrutinib showed a 31% delay in the onset of confirmed disability progression in a phase 3 study of non-relapsing secondary progressive multiple sclerosis.
Read →
Positive Phase 1a Safety, Tolerability, and PK/PD Results for Tectonic Therapeutic's TX45
Latest Hotspot
3 min read
Positive Phase 1a Safety, Tolerability, and PK/PD Results for Tectonic Therapeutic's TX45
24 September 2024
Tectonic Therapeutic Shares Positive Safety, Tolerability, and PK/PD Phase 1a Results for Lead Candidate TX45.
Read →
Small RNA Drugs: Therapeutic Strategies, Sequence Analysis, and Chemical Modifications
Bio Sequence
7 min read
Small RNA Drugs: Therapeutic Strategies, Sequence Analysis, and Chemical Modifications
24 September 2024
siRNA and ASO are two nucleic acid-based gene silencing technologies that achieve precise regulation of gene expression by complementary pairing with specific mRNA sequences.
Read →
Promising Phase 1 Results for Trishula Therapeutics' TTX-030 in Metastatic Pancreatic Cancer
Latest Hotspot
4 min read
Promising Phase 1 Results for Trishula Therapeutics' TTX-030 in Metastatic Pancreatic Cancer
24 September 2024
Trishula Therapeutics' Phase 1 trial of TTX-030 shows encouraging results for first-line treatment of metastatic pancreatic cancer.
Read →
Zealand: Latest Developments in the Insulin Analog Petrelintide for Weight Management
Hot Spotlight
3 min read
Zealand: Latest Developments in the Insulin Analog Petrelintide for Weight Management
24 September 2024
the Danish pharmaceutical company Zealand Pharma announced clinical Phase 1 data for its long-acting amylin analogue, Petrelintide, which is being studied for weight management.
Read →
Beacon Therapeutics Releases 36-Month Data on AGTC-501 from HORIZON Phase I/2 Trial for XLRP
Latest Hotspot
3 min read
Beacon Therapeutics Releases 36-Month Data on AGTC-501 from HORIZON Phase I/2 Trial for XLRP
24 September 2024
Beacon Therapeutics Shares 36-Month Interim Data from HORIZON Phase I/2 Trial of AGTC-501 for XLRP Patients.
Read →
Novo Nordisk: A long-acting, selective human insulin analog, NN1213, for weight management
Hot Spotlight
4 min read
Novo Nordisk: A long-acting, selective human insulin analog, NN1213, for weight management
24 September 2024
Amylin is a pancreatic peptide consisting of 37 amino acids that is co-stored and co-secreted with insulin in response to nutrient intake.
Read →
RYBREVANT® Approved in U.S. as Exclusive Second-Line Targeted Treatment for EGFR-Mutated Advanced Lung Cancer
Latest Hotspot
4 min read
RYBREVANT® Approved in U.S. as Exclusive Second-Line Targeted Treatment for EGFR-Mutated Advanced Lung Cancer
24 September 2024
RYBREVANT® (amivantamab-vmjw) with standard care now approved in the U.S. as the sole targeted treatment reducing disease progression risk by over 50% for second-line EGFR-mutated advanced lung cancer.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Sep 24
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Sep 24
24 September 2024
Sep 24th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Edgewise Therapeutics Announces Positive Phase 1 and Phase 2 CIRRUS-HCM Study Results in Obstructive Hypertrophic Cardiomyopathy
Latest Hotspot
4 min read
Edgewise Therapeutics Announces Positive Phase 1 and Phase 2 CIRRUS-HCM Study Results in Obstructive Hypertrophic Cardiomyopathy
24 September 2024
Edgewise Therapeutics Reports Favorable Results from Phase 1 Study in Healthy Volunteers and Phase 2 CIRRUS-HCM Study in Obstructive Hypertrophic Cardiomyopathy Patients.
Read →
4DMT Highlights Promising Clinical Results for 4D-150 and Reveals Phase 3 Strategy at Wet AMD Program Event
Latest Hotspot
4 min read
4DMT Highlights Promising Clinical Results for 4D-150 and Reveals Phase 3 Strategy at Wet AMD Program Event
24 September 2024
4DMT Showcases Strong and Lasting Clinical Outcomes for 4D-150 and Unveils 4FRONT Phase 3 Program Plan at 4D-150 Wet AMD Development Event.
Read →